MEK 抑制剂相关性眼压升高

Ocular Oncology and Pathology Pub Date : 2023-11-30 DOI:10.1159/000535427

David A. Collet, Julia Canestraro, Ghassan K. Abou-Alfa, David H. Abramson, Eli L. Diamond, J. Francis

{"title":"MEK 抑制剂相关性眼压升高","authors":"David A. Collet, Julia Canestraro, Ghassan K. Abou-Alfa, David H. Abramson, Eli L. Diamond, J. Francis","doi":"10.1159/000535427","DOIUrl":null,"url":null,"abstract":"Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.","PeriodicalId":506981,"journal":{"name":"Ocular Oncology and Pathology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MEK Inhibitor-Associated Ocular Hypertension\",\"authors\":\"David A. Collet, Julia Canestraro, Ghassan K. Abou-Alfa, David H. Abramson, Eli L. Diamond, J. Francis\",\"doi\":\"10.1159/000535427\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.\",\"PeriodicalId\":506981,\"journal\":{\"name\":\"Ocular Oncology and Pathology\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ocular Oncology and Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000535427\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000535427","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

丝裂原活化蛋白激酶激酶（MEK）抑制剂是一种靶向抗癌药，可用于治疗多种癌症。尽管MEK抑制剂疗效显著，但也存在眼部毒性，其中最明显的是神经视网膜的自限性浆液性脱离。在本报告中，我们概述了三例罕见的毒性病例--MEK 抑制剂相关性眼压升高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MEK Inhibitor-Associated Ocular Hypertension

Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ocular Oncology and Pathology

自引率

0.00%

发文量